ASMB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.42M

+0.89%

-0.650

-58.6%

9.30M

-1.26%

-0.500

-57.26%

8.30M

-13.78%

-0.490

-63.16%

Estimates Revision

The market is revising No Change the revenue expectations for Assembly Biosciences, Inc. (ASMB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 17.67%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+17.67%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ASMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASMB is 41.75 USD with a low forecast of 38.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

38.00

Averages

41.75

High

50.00

Current: 0.000

Low

38.00

Averages

41.75

High

50.00

Mizuho

Salim Syed

maintain

$29 -> $40

2025-11-20

Reason

Mizuho

Salim Syed

Price Target

$29 -> $40

2025-11-20

maintain

Reason

Mizuho analyst Salim Syed raised the firm's price target on Assembly Biosciences to $40 from $29 and keeps an Outperform rating on the shares. The firm updated the company's model to reflect the recent positive ABI-5366 data.

Citizens JMP

Roy Buchanan

Outperform

initiated

$38

2025-09-24

Reason

Citizens JMP

Roy Buchanan

Price Target

$38

2025-09-24

initiated

Outperform

Reason

Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences with an Outperform rating and $38 price target. The firm believes the company's \"strong early data point to likely best-in-class profiles\" for both its oral candidates for treating herpes simplex virus is underappreciated at current share levels. Assembly's lead opportunity in treating recurrent genital herpes has blockbuster potential, the analyst tells investors in a research note.

Guggenheim

Buy

upgrade

$31 -> $39

2025-09-08

Reason

Guggenheim

Price Target

$31 -> $39

2025-09-08

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Assembly Biosciences to $39 from $31 and keeps a Buy rating on the shares. Following interim data from Assembly's Phase 1b study released last month that demonstrated "striking efficacy and a clean safety profile" for ABI-5366, the firm is increasing its view of the odds of success to 75% from 65% and increasing its assumed monthly price to $500 from $300 for what it calls "a potential blockbuster novel weekly or monthly treatment" for recurrent genital herpes.

H.C. Wainwright

Patrick Trucchio

initiated

$50

2025-08-18

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$50

2025-08-18

initiated

Reason

H.C. Wainwright analyst Patrick Trucchio assumed coverage of Assembly Biosciences with a Buy rating and $50 price target. The firm sees potential for the company's clinical-stage antiviral pipeline to deliver "significant value" in collaboration with Gilead Sciences (GILD).

Guggenheim

Vamil Divan

Strong Buy

Initiates

$31

2025-03-25

Reason

Guggenheim

Vamil Divan

Price Target

$31

2025-03-25

Initiates

Strong Buy

Reason

Guggenheim initiated coverage of Assembly Biosciences with a Buy rating and $31 price target.

HC Wainwright & Co.

Ed Arce

Hold

Reiterates

n/a

2025-03-24

Reason

HC Wainwright & Co.

Ed Arce

Price Target

n/a

2025-03-24

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Assembly Biosciences Inc (ASMB.O) is -15.92, compared to its 5-year average forward P/E of -2.37. For a more detailed relative valuation and DCF analysis to assess Assembly Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.37

Current PE

-15.92

Overvalued PE

0.70

Undervalued PE

-5.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.58

Current EV/EBITDA

-6.28

Overvalued EV/EBITDA

1.32

Undervalued EV/EBITDA

-2.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.13

Current PS

17.60

Overvalued PS

35.64

Undervalued PS

-13.37

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 161.98% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ASMB News & Events

Events Timeline

No data

News

7.5

2025-12-22Benzinga

Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment

7.5

2025-12-22NASDAQ.COM

Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment

7.5

2025-12-22SeekingAlpha

Gilead Activates License for Assembly Biosciences' Herpes Initiatives

People Also Watch

Frequently Asked Questions

What is Assembly Biosciences Inc (ASMB) stock price today?

The current price of ASMB is 31.56 USD — it has increased 0.54 % in the last trading day.

What is Assembly Biosciences Inc (ASMB)'s business?

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

What is the price predicton of ASMB Stock?

What is Assembly Biosciences Inc (ASMB)'s revenue for the last quarter?

Assembly Biosciences Inc revenue for the last quarter amounts to 10.79M USD, increased 57.62 % YoY.

What is Assembly Biosciences Inc (ASMB)'s earnings per share (EPS) for the last quarter?

Assembly Biosciences Inc. EPS for the last quarter amounts to -0.72 USD, decreased -52.32 % YoY.

What changes have occurred in the market's expectations for Assembly Biosciences Inc (ASMB)'s fundamentals?

How many employees does Assembly Biosciences Inc (ASMB). have?

Assembly Biosciences Inc (ASMB) has 73 emplpoyees as of January 09 2026.

What is Assembly Biosciences Inc (ASMB) market cap?

Today ASMB has the market capitalization of 499.19M USD.